Convergence Investment Partners LLC Buys 10,766 Shares of Halozyme Therapeutics, Inc. $HALO

Posted by Francis Steltz on May 16th, 2026

Convergence Investment Partners LLC boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 53.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,851 shares of the biopharmaceutical company’s stock after purchasing an additional 10,766 shares during the period. Convergence Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $2,076,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Moran Wealth Management LLC grew its position in Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 151 shares during the period. Coldstream Capital Management Inc. boosted its stake in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 165 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Halozyme Therapeutics by 3.0% during the 3rd quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 170 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the last quarter. Finally, Private Advisor Group LLC boosted its stake in shares of Halozyme Therapeutics by 0.8% during the 3rd quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company’s stock worth $1,733,000 after acquiring an additional 184 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 3.0%

HALO opened at $67.12 on Friday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 3.66 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a fifty-two week low of $48.64 and a fifty-two week high of $82.22. The firm’s fifty day moving average is $65.65 and its 200 day moving average is $68.64. The stock has a market cap of $7.96 billion, a price-to-earnings ratio of 24.14, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter in the previous year, the company earned $1.11 EPS. Halozyme Therapeutics’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $49,322,187.20. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the transaction, the chief operating officer owned 14,366 shares in the company, valued at approximately $974,014.80. This trade represents a 58.20% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 120,482 shares of company stock worth $8,200,842. 2.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

HALO has been the topic of several analyst reports. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday. HC Wainwright lifted their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Benchmark lifted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Get Our Latest Analysis on HALO

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.